Article

Accommodative lens outcomes less than stellar

An evaluation of four randomized clinical trials found no evidence to recommend the use of accommodative IOLs, said Hon Shing Ong, MBBS.

Orlando-An evaluation of 4 randomized clinical trials found no evidence to recommend the use of accommodative IOLs, said Hon Shing Ong, MBBS.

Participants who received accommodative IOLs had improvements in near vision at 6 months and at 12 months after surgery, compared with those who received monofocal IOLs.

“(But) such improvements were small and reduced with time,” said Dr. Ong, Moorfields Eye Hospital, London.

Dr. Ong’s group searched the Cochrane Central Register of Controlled Trials, and found 256 eyes (148 in the accommodative group and 108 in the monofocal group). All eyes that received an accommodative lens were implanted with the HumanOptics 1CU.

 

Compared with the monofocal group, the accommodative IOL group had significantly higher amplitude of accommodation at 6 months post treatment measured by near point of accommodation (mean difference [MD] 1.43 D; 95% CI 0.79 to 2.07) and defocus curves (MD 0.47 D; 95% CI 0.36 to 0.59).

“At 12 months, patients in the accommodative group had worse corrected distance visual acuity than those in the monofocal group,” he said. “There was a higher rate of posterior capsular opacification (PCO) in the accommodative group.”

The lower levels of distance vision may be related to the increased PCO, but findings were not definitive, Dr. Ong said.

 

“The small gains in distance corrected visual acuity were not clinically significant,” he said. “Further research is necessary before we can draw conclusions on accommodative lens efficacy and safety compared with monofocal IOLs.”

 

For more articles in this issue of Ophthalmology Times’ Conference Brief, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.